3-(2-fluorenyl)-D,L-alanine | 889888-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 3-(2-fluorenyl)-D,L-alanine
• 英文别名: (2S)-2-amino-3-(9H-fluoren-2-yl)propanoic acid
• CAS: 889888-46-4
• 化学式: C₁₆H₁₅NO₂
• 分子量: 253.301
• InChiKey: GLWFDTWIDROQIY-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone, their preparation and pharmaceutical compositions containing them
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0021234A1

  公开（公告）日：1981-01-07

  Nonapeptide and decapeptide analogs of LH-RH of the formula (pyro)Glu-His-V-Ser-W-X-Y-Arg-Pro-Z (I) and the pharmaceutically acceptable salt thereof wherein: V is tryptophyl, phenylalanyl or 3-(1-naphthyl)-L-alanyl; W is tyrosyl, phenylalanyl or 3-(1-pentafluorophenyl)-L-alanyl; X is a D-amino acid residue wherein R is (a) a carbocyclic aryl-containing radical selected from the group consisting of naphthyl, anthryl, fluorenyl, phenanthryl, biphenylyl, benzhydryl and phenyl substituted with three or more straight chain lower alkyl groups; or (b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenylyl, perhydro-2,2-diphenylmethyl and adamantyl; Y is leucyl, isoleucyl, nor-leucyl or N-methyl-leucyl; Z is glycinamide or-NH-R1, wherein R' is lower alkyl, cycloalkyl, fluoro lower alkyl or wherein R2 is hydrogen or lower alkyl, are disclosed. These compounds exhibit potent LH-RH agonist properties.

  式中的 LH-RH 的非肽和十肽类似物 (焦)Glu-His-V-Ser-W-X-Y-Arg-Pro-Z (I)及其药学上可接受的盐 其中： V 是色氨酰、苯丙氨酰或 3-(1-萘基)-L-丙氨酰； W 是酪氨酰基、苯丙氨酰基或 3-(1-五氟苯基)-L-丙氨酰； X 是 D-氨基酸残基，其中 R 是 (a) 一个含碳环芳基，选自由萘基、蒽基、芴基、菲基、联苯基、苯hydryl 和被三个或三个以上直链低级烷基取代的苯基组成的组；或 (b) 饱和碳环基，选自由三个或三个以上直链低级烷基取代的环己基、全氢萘 基、全氢联苯基、全氢-2,2-二苯基甲基和金刚烷基组成的组； Y 是亮氨酰、异亮氨酰、去亮氨酰或 N-甲基亮氨酰； Z 是甘氨酰胺或-NH-R1，其中 R' 是低级烷基、环烷基、氟低级烷基或 其中 R2 是氢或低级烷基。这些化合物具有强效的 LH-RH 激动剂特性。
• Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists, methods of making them, and their pharmaceutical uses
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0049628A2

  公开（公告）日：1982-04-14

  Nonapeptide and decapeptide analogs of LHRH which have the formula and the pharmaceutically acceptable salts thereof, wherein: X is a D-alanyl residue wherein one hydrogen on C-3 is replaced by: a) a carbocyclic aryl-containing radical selected from the group consisting of phenyl substituted with three or more straight chain lower alkyl groups, naphthyl, anthryl, fluorenyl, phenanthryl, biphenylyl and benzhydryl; or b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenylyl, perhydro-2,2-diphenylmethyl, and adamantyl; or c) a heterocyclic aryl containing radical selected from the group consisting of radicals represented by the following structural formulas: wherein A" and A' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine, and bromine, and G is selected from the group consisting of oxygen, nitrogen, and sulfur; A is an aminoacyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-L-prolyl, N-acyl-D-prolyl, N-acyl-D-tryptophanyl, N-acyl-D-phenylalanyl, N-acyl-D-p-halophenylalanyl, and N-acyl-X wherein X is as defined previously; B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-halophenylalanyl, 2,2-diphenylglycyl, and X wherein X is as defined previously; C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl and X wherein X is as defined above; E is glycinamide or -NH-R1, wherein R1 is lower alkyl, cycloalkyl, fluoro lower alkyl or R2 is hydrogen or lower alkyl; are disclosed. These compounds are LHRH antagonists.

  LHRH 的非肽和十肽类似物，其分子式为 及其药学上可接受的盐类，其中 X是D-丙氨酰残基，其中C-3上的一个氢被下列物质取代 a) 一个含碳环芳基，选自由三个或三个以上直链低级烷基取代的苯基、萘基、蒽基、芴基、菲基、联苯基和二苯基组成的组；或 b) 饱和碳环基，选自由三个或三个以上直链低级烷基取代的环己基、过氢萘基、过氢联苯基、过氢-2,2-二苯基甲基和金刚烷基组成的组；或 c) 杂环芳基，选自由下列结构式所代表的基团组成的组： 其中 A "和 A'独立地选自氢、低级烷基、氯和溴组成的组，G 选自氧、氮和硫组成的组； A 是氨基酰基残基，选自由 L-焦谷氨酰、D-焦谷氨酰、N-酰基-L-脯氨酰、N-酰基-D-脯氨酰、N-酰基-D-色氨酰、N-酰基-D-苯丙氨酰、N-酰基-D-对卤苯丙氨酰和 N-酰基-X 所组成的组，其中 X 如前定义； B 是选自 D-苯丙氨酰、D-对卤代苯丙氨酰、2,2-二苯基甘氨酰和 X 所组成的组的氨基酰基残基，其中 X 如前所定义； C 是氨基酰基残基，选自由 L-色氨酰、D-色氨酰、D-苯丙氨酰和 X 所组成的组，其中 X 如前所定义； E 是甘氨酰胺或-NH-R1，其中 R1 是低级烷基、环烷基、氟低级烷基或-NH-R1。 R2 是氢或低级烷基； 这些化合物是 LHRH 拮抗剂。这些化合物是 LHRH 拮抗剂。
• Nouveaux composés octapeptidiques et leur utilisation thérapeutique
  申请人：IPSEN PHARMA

  公开号：EP2168983A1

  公开（公告）日：2010-03-31

  La présente invention concerne de nouveaux composés octapeptidiques de formule générale (I).          H-2-Nal1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2     (I) Ces produits ayant une bonne affinité pour certains sous-types de récepteurs de la somatostatine, ils sont particulièrement intéressants pour traiter les états pathologiques ou les maladies dans lesquels un (ou plusieurs) des récepteurs de la somatostatine est (sont) impliqué(s). Ces produits ayant également des propriétés d'assemblage particulières, ils sont particulièrement intéressants pour la formulation de médicaments. L'invention concerne donc également des compositions pharmaceutiques contenant lesdits produits et leur utilisation pour la préparation d'un médicament.

  本发明涉及通式（I）的新八肽化合物。 H-2-Nal1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2 (I) 由于这些产品对某些体生长抑素受体亚型具有良好的亲和力，因此它们特别适用于治疗涉及一种（或多种）体生长抑素受体的病理状态或疾病。由于这些产品还具有特殊的装配特性，因此它们在配制药物方面也具有特别的意义。因此，本发明还涉及含有上述产品的药物组合物及其在制备药物中的用途。
• NOUVEAUX COMPOSES OCTAPEPTIDIQUES DERIVES DE LA SOMATOSTATINE ET LEUR UTILISATION THERAPEUTIQUE
  申请人：IPSEN PHARMA S.A.S.

  公开号：EP2344529A1

  公开（公告）日：2011-07-20
• NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF
  申请人：Paternostre Marie-Thérèse

  公开号：US20110178013A1

  公开（公告）日：2011-07-21

  The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1 -cyclo(Cys 2 -Tyr 3 -AA 4 -Lys 5 -Val 6 -Cys 7 )-Thr 8 -NH 2 . Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.